Analysis of vaccination against HPV in Brazil according to the goals implemented for 2030 by the World Health Organization
DOI:
https://doi.org/10.33448/rsd-v12i4.40845Keywords:
HPV; Vaccine; Cervical cancer.Abstract
The HPV vaccine is currently the best way to prevent cervical cancer. Through a retrospective study, this work aimed to collect data on the distribution of vaccines against HPV in Brazil, evaluating the percentage of doses distributed, since the country has committed itself to the World Health Organization (WHO) to reach the global goal 90% vaccination coverage of girls before the age of 15 by 2030. The data were obtained using the TabNet algorithm developed by DATASUS and the results showed that the number of immunizations against HPV was higher in the years 2014 and 2015, with 7,874 .743 and 5,774,727 doses distributed respectively, and less in 2022 with 2,050,724 doses. In the analysis by applied doses, between 2014 and 2022 there was a 73.90% reduction in the number of doses, in addition the distribution of the vaccine was smaller for the 2nd dose both in the year 2014 and in the year 2022. Although it is scientifically proven that vaccine against HPV is extremely relevant for the reduction in the number of cases of CC in primary prevention, the findings of this study point to a considerable reduction in the demand for this vaccine over the last nine years. The impact of Fake news would be one of those responsible for the decrease in the number of immunizations in the country, aggravated by the interruption of vaccination during the COVID-19 Pandemic. It is urgent for Brazil to use more effective strategies to achieve the global goal of immunizations.
References
Avaaz & SBIm. (2019). As Fake News estão nos deixando doentes? https://sbim.org.br/images/files/po-avaaz-relatorio-antivacina.pdf.
Bouvard, V. et al. (2021). The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine. 385(20), 1908–18, 11. https://doi.org/10.1056/nejmsr2030640.
Brasil. (2015). Vacina contra HPV para meninas entre 9 e 11 anos está disponível no SUS. Fundação Osvaldo Cruz (Fiocruz). https://portal.fiocruz.br/noticia/vacina-contra-hpv-para-meninas-entre-9-e-11-anos-esta-disponivel-no-sus.
Brotherton, J. M. L., & Bloem, P. N. (2018). Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 42–58. https://doi.org/10.1016/j.bpobgyn.2017.08.010.
Bruni, L. et al. (2021). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine, 144, 106399. https://doi.org/10.1016/j.ypmed.2020.106399.
Calumby, R. J. N. et al. (2020). Papiloma Vírus Humano (HPV) e neoplasia cervical: importância da vacinação. Brazilian Journal of Health Review, 3(2), 1610–1628. https://doi.org/10.34119/bjhrv3n2-023.
Castro, B. T. de, Quaresma, A. L. P., Azevêdo, A. O., Silva, L. M. da, & Teixeira, C. S. S. (2022). Cobertura de doses da vacina contra HPV e variação por nível de privação material dos municípios brasileiros, 2012 a 2018. Research, Society and Development, 11(13). https://doi.org/10.33448/rsd-v11i13.35484.
Cavalcante, R. L., Damasceno, H. C., Silva Júnior, A. F. da, & Pinheiro, M. da C. N. (2021). Impacto da pandemia por COVID-19 na imunização da vacina contra o Papilomavírus Humano entre crianças e adolescentes de 9 a 14 anos na região do Xingu - Pará. Research, Society and Development, 10(4). https://doi.org/10.33448/rsd-v10i4.13987.
Falcaro, M. et al. (2021). The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. The Lancet. https://doi.org/10.1016/S0140-6736(21)02178-4.
Ferraro, C. T. L., Canedo, N. H. S., Oliveira, S. P. de, Carvalho, M. da G. da C., & Dias, E. P. (2011). HPV oral infection and proliferative epithelial associated lesions. Jornal Brasileiro de Patologia E Medicina Laboratorial, 47(4), 451–459. https://doi.org/10.1590/S1676-24442011000400010.
Ferreira, F. V., & Varão, R. (2021). Noticias falsas y VPH: relaciones entre comunicación e información para la prevención de enfermedades y la promoción de la salud para niños y niñas. Razón Y Palabra, 25(110). https://doi.org/10.26807/rp.v25i110.1741.
Filho, A. S., Dourado, P., & Vieira, L. (2021). Lockdown e outras intervenções não farmacológicas. Conecta SUS. https://www.saude.go.gov.br/files//banner_coronavirus/protocolos-notas/S%C3%ADnteses%20de%20Evid%C3%AAncias/2021/Lockdown.pdf.
Galvão, M. P. S. P., Araújo, T. M. E. de, & Rocha, S. S. da. (2022). Conhecimentos, atitudes e práticas de adolescentes sobre o papilomavírus humano. Revista de Saúde Pública, 56, 12. https://doi.org/10.11606/s1518-8787.2022056003639.
Laurent, J., Luckett, R., & Feldman, S. (2018). HPV vaccination and the effects on rates of HPV-related cancers. Current Problems in Cancer, 42(5), 493–506. https://doi.org/10.1016/j.currproblcancer.2018.06.004.
Lei Ordinária 19534 2018 do Paraná PR. (2018). Leisestaduais.com.br. https://leisestaduais.com.br/pr/lei-ordinaria-n-19534-2018-parana-dispoe-sobre-a-obrigatoriedade-da-apresentacao-da-carteira-de-vacinacao-no-at-da-carteira-de-vacinacao-no-at.
Lorenzi, A. T., Syrjänen, K. J., & Longatto-Filho, A. (2015). Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspective. Virology Journal, 12(1). https://doi.org/10.1186/s12985-015-0342-0.
Machado, L. S., & Pires, M. C. (2018). Perfil epidemiológico de mulheres com Papilomavírus Humano que utilizam o serviço público de saúde. Revista Baiana De Enfermagem, 31(4). https://doi.org/10.18471/rbe.v31i4.22135.
Marchetti, R. L., Gallucci-Neto, J., Kurcgant, D., Proença, I. C. G. F., Valiengo, L. da C. L., Fiore, L. A., Pinto, L. F., Maranhão, A. G. K., Oliveira, M. T. da C., & de Oliveira, L. H. (2020). Immunization stress-related responses presenting as psychogenic non-epileptic seizures following HPV vaccination in Rio Branco. Brazil. Vaccine, 38(43), 6714–6720. https://doi.org/10.1016/j.vaccine.2020.08.044.
Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer, 141(4), 664–670. https://doi.org/10.1002/ijc.30716.
Ministério da Saúde. (2014). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Incidência de Câncer no Brasil. https://www.inca.gov.br/bvscontrolecancer/publicacoes/Estimativa_2014.pdf.
Ministério da Saúde. (2019). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020. Incidência de Câncer no Brasil. https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf.
Ministério da Saúde. (2020). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estatísticas de câncer no Brasil. https://www.inca.gov.br/numeros-de-cancer.
Ministério Da Saúde. (2021). Saúde amplia vacinação contra HPV para mulheres imunossuprimidas com até 45 anos. https://www.gov.br/saude/pt-br/assuntos/noticias/2021-1/marco/saude-amplia-vacinacao-contra-hpv-para-mulheres-imunossuprimidas-com-ate-45-anos.
Ministério da Saúde. (2022). Instituto Nacional de Câncer José Alencar Gomes da SIlva (INCA). Dados e números sobre o câncer de colo do útero. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//dados_e_numeros_colo_22setembro2022.pdf.
Ministério da Saúde. (2022). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Dados e números sobre câncer de colo do útero. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document/dados_e_numeros_colo_22novembro2022_0.pdf.
Ministério da Saúde. (2022). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Fatores de risco. https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-do-colo-do-utero/fatores-de-risco.
Nota informativa no 311/2016/CGPNI/DEVIT/SVS/MS | Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. (2016). Antigo.aids.gov.br. http://antigo.aids.gov.br/pt-br/legislacao/nota-informativa-no-3112016cgpnidevitsvsms.
Moura, L. de L., Codeço, C. T., & Luz, P. M. (2021). Cobertura da vacina papilomavírus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes etárias. Revista Brasileira de Epidemiologia, 24. https://doi.org/10.1590/1980-549720210001.
OPAS/OMS. (2021). Organização Pan-Americana da Saúde. Novas recomendações de rastreio e tratamento para prevenir o câncer do colo do útero. www.paho.org. https://www.paho.org/pt/noticias/6-7-2021-novas-recomendacoes-rastreio-e-tratamento-para-prevenir-cancer-do-colo-do-utero.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Piotto, K. L., Utzig, E. K., Motter, N. S., Yamada, R. S., & Prates, R. T. C. (2020). Principais tipos de HPV presentes na carcinogênese da neoplasia maligna da orofaringe: uma revisão de literatura. Brazilian Journal of Development, 6(6), 42002–42009. https://doi.org/10.34117/bjdv6n6-657.
SBIm. (2023). Vacina HPV4. https://familia.sbim.org.br/vacinas/vacinas-disponiveis/vacina-hpv4.
Silva, M. L., Nunes, J. S. S., Oliveira, K. S. de, & Leite, T. A. S. (2020). Conhecimento de mulheres sobre câncer de colo do útero: Uma revisão integrativa. Brazilian Journal of Health Review, 3(4), 7263–7275. https://doi.org/10.34119/bjhrv3n4-005.
Souza, G. da C. S., Silva, E. R. da, Macêdo, F. L. dos S., Soares, L. R. C., Rosal, V. M. de S., & Rocha, M. G. de L. (2015). Papilomavírus humano: biologia viral e carcinogênese. Femina, 189–192. https://pesquisa.bvsalud.org/portal/resource/pt/lil-771212.
Taquary, L. R., Acioli, M. L. B., Aires, M. M. G., Mendonça, P. H. R. de, Barbosa, R. de S. B., & Moura, L. R. M. (2018). Fatores de risco associados ao PapilomavírusHumano (HPV) e o desenvolvimento de lesões carcinogênicas no colo do útero: uma breve revisão. CIPEEX, 2, 855–859. http://anais.unievangelica.edu.br/index.php/CIPEEX/article/view/3042/1327.
Tsua, V., LaMontagne, D.S., Atuhebwe, P., Bloem, P.N., & Ndiaye, C. (2021). National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects. Preventive Medicine, 144, 106335. https://doi.org/10.1016/j.ypmed.2020.106335.
Tsuchiya, C., Lawrence, T., Klen, M., Fernandes, R., & Alves, M. R. (2017). O câncer de colo do útero no Brasil: uma retrospectiva sobre as políticas públicas voltadas à saúde da mulher. Jornal Brasileiro de Economia Da Saúde, 9(1), 137–147. https://doi.org/10.21115/jbes.v9.n1.p137-47.
Wanderley, M. da S. et al. (2021). Medical students’ knowledge of the human papillomavirus (HPV), cervical cancer, and HPV vaccination. Revista Brasileira de Educação Médica, 45(3). https://doi.org/10.1590/1981-5271v45.3-20210071.ing.
World Health Organization: Weekly Epidemiological Record (WER). Vol. 97, n 50, 2022, pp. 645–672. WHO (2022). https://reliefweb.int/report/world/weekly-epidemiological-record-wer-16-december-2022-vol-97-no-50-2022-pp-645-672-enfr.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Raquel Justakowski Lopes; Rita de Cássia Garcia Simão; Maurício Turkiewicz; Jacqueline Plewka
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
